Mechanical ventilation is a life-saving therapy in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS) although it may induce ventilator-induced lung injury (VILI) ([@R1]--[@R7]). The highest quality of evidence demonstrates that a volume control (VC) ventilation strategy using low tidal volume (LTV) of 6 mL/kg of predicted body weight (PBW) with plateau pressure (P~plat~) less than 30 cm H~2~O reduces mortality in patients with ARDS compared with a target tidal volume (V~T~) equal to 12 mL/kg PBW and P~plat~ less than 50 cm H~2~O ([@R1]). V~T~s even 1 or 2 mL/kg above LTV in patients with ARDS are associated with increased mortality ([@R8]). Many clinicians advocate for LTV ventilation for treatment of ARDS, with some arguing benefit in patients without ARDS ([@R9]--[@R12]).

Airway pressure release ventilation (APRV) is a pressure-limited mode of mechanical ventilation observed to improve oxygenation ([@R13]--[@R17]).

APRV is proposed as an alternative to VC-LTV because it attempts to minimize time spent at a low positive end-expiratory pressure (PEEP, or P~low~) and increase mean airway pressure (P~aw~) by maximizing time spent at a high PEEP, or P~high~, but it does not target release volumes ([@R14], [@R18], [@R19]). Early studies of APRV demonstrate improvements in patient's oxygenation with lower peak inspiratory pressures (PIPs) and higher P~aw~s compared to patients treated with conventional ventilation ([@R20]--[@R23]). Observational studies also suggest an improved hemodynamic profile and enhanced patient comfort (both related to spontaneous breathing) resulting in reduced sedation requirements with APRV ([@R24]--[@R27]). PEEP optimization may improve oxygenation but occurs at the expense of higher measured tidal or release volumes that could increase VILI ([@R28], [@R29]). Therefore, we created an exportable APRV-LTV protocol that adapted the Habashi ([@R14]) protocol to employ an LTV ventilation strategy that targets average release volumes less than 6.5 mL/kg.

We proposed APRV-LTV would confer the benefits of APRV and limit the risk of VILI ([@R14], [@R18]). An ideal APRV-LTV protocol is reproducible and generalizable, enhances patient comfort, and confers advantages to hemodynamics and clinically relevant endpoints. We defined feasibility as successful implementation of an APRV-LTV protocol that consistently achieved V~T~ less than or equal to 6.5 mL/kg with high clinician compliance. Before conducting a large multicenter efficacy trial comparing mortality between APRV-LTV and VC-LTV, we assessed the feasibility of an APRV-LTV protocol compared with traditional APRV and VC in a randomized, three-arm design among patients with acute hypoxemic respiratory failure.

METHODS
=======

We performed a randomized controlled feasibility trial of VC-LTV versus APRV-LTV versus APRV in patients with respiratory failure admitted to one of four ICUs located in three Intermountain Healthcare hospitals over 49 months with first enrollment in September 2011 after trial registration with clinical.trials.gov (NCT01339533). The Central Region Intermountain Institutional Review Board (IRB) approved the protocol (IRB number: 1015758) with oversight from an independent data safety and monitoring board (DSMB). We employed three explicit mechanical ventilation paper protocols in patients with respiratory failure less than 24 hours and anticipated to require the ventilator for greater than 24 hours. Patients were assigned via computer-generated permuted 3--6 block randomization with sealed, opaque, and sequentially numbered envelopes into one of three arms: 1) conventional VC-LTV ventilation, 2) APRV-LTV, and 3) traditional APRV ([@R14]) (**Supplement A**, Supplemental Digital Content 1, <http://links.lww.com/CCM/E39>; **Supplement B**, Supplemental Digital Content 2, <http://links.lww.com/CCM/E40>; and **Supplement C**, Supplemental Digital Content 3, <http://links.lww.com/CCM/E41>). An identical continuous positive airway pressure protocol with a trigger F[io]{.smallcaps}~2~ less than or equal to 0.60 and a PEEP or P~high~ less than or equal to 10 comprised the weaning phase, which is found in Supplement B, along with daily compliance (**Supplement D**, Supplemental Digital Content 4, <http://links.lww.com/CCM/E42>) and power analysis (**Supplement E**, Supplemental Digital Content 5, <http://links.lww.com/CCM/E43>) for planned enrollment of the initial study aimed to justify a larger multicenter efficacy trial. The study was terminated early to maximize enrollment in Prevention and Early Treatment of Acute Lung Injury Network competing trials and after a planned 50 patient data review by the DSMB revealed significant variability in V~T~s in the APRV-LTV protocol.

Protocols
---------

We operationalized the three protocols with decision tree logic for adhering to each arm's stated purpose (Supplement A, Supplemental Digital Content 1, <http://links.lww.com/CCM/E39>; Supplement B, Supplemental Digital Content 2, <http://links.lww.com/CCM/E40>; and Supplement C, Supplemental Digital Content 3, <http://links.lww.com/CCM/E41>). We used the Draeger EvitaXL ventilator (Draeger, Houston, TX) for all protocols. Each protocol was written in paper format with cell branching logic as a preliminary step for computerization and exportability. The VC-LTV titrates PEEP and F[io]{.smallcaps}~2~ based on the ARDS Network (ARDSNet) recommended F[io]{.smallcaps}~2~ and PEEP tables modified for high altitude ([@R1], [@R30]). The oxygenation and ventilation tables were used by our institution in ARDSNet trials. The VC-LTV protocol sets a target V~T~ of 6.0 mL/kg but with auto-flow can result in measured V~T~ greater than 6.0 mL/kg. Release volumes and V~T~s are measured as exhale volumes at the exhalation valve of the ventilator. Respiratory therapists interact with the patient and the ventilator at least every 2 hours, often more frequently, and record the average values over several breaths in the electronic ventilator record. APRV-LTV titrates P~low~ and/or P~high~ to target release volumes equal to 6.0 mL/kg. Traditional APRV followed previously published protocols ([@R14]) (Supplement C, Supplemental Digital Content 3, <http://links.lww.com/CCM/E41>). APRV-LTV was developed by two respiratory therapists and three pulmonary and critical care physicians and involved testing in an artificial lung simulation laboratory with quality improvement project iterative refinement of the protocol during clinical care (Supplement B, Supplemental Digital Content 2, <http://links.lww.com/CCM/E40>). All participating clinicians stated equipoise regarding the study.

After randomization, the respiratory therapist set the ventilator parameters per the specific arm protocol directions. APRV settings were determined by setting P~high~ 3 above the P~aw~ reading for the patient before randomization. Traditional APRV settings followed the Habashi ([@R14]) protocol to set P~low~ equal to 0 with time~high~ and P~low~ titrated per patient response. APRV-LTV settings were determined by setting P~high~ 3 above the P~aw~ reading for the patient before randomization. P~low~ was set at a minimum of 5 and titrated with P~high~ to target a release volume equals to 6 mL/kg. Work of breathing for each patient was observed and adjusted for P.01 as described in the protocol (Supplement B, Supplemental Digital Content 2, <http://links.lww.com/CCM/E40>; and Supplement C, Supplemental Digital Content 3, <http://links.lww.com/CCM/E41>).

Data Collection
---------------

As part of standard clinical practice, respiratory therapists measure and electronically record ventilator parameters every 2 hours, including P~aw~, PIP, V~T~, exhaled volume, and P~plat~ when indicated. We report average daily ventilator parameters. V~T~ (mL/kg PBW) was defined as the measured exhaled volume for the VC-LTV and the measured exhaled release volume each APRV arm. We also collected the exhaled volume and rate of spontaneous breaths in the APRV arms. P~high~ and PIP were treated as interchangeable for APRV, and P~plat~ is not measured. Lowest mean arterial pressure (MAP) and average daily central venous pressure (CVP) were also recorded. The medication dosing data were reported for baseline day as randomization time to 6:00 [am]{.smallcaps} the following day, and then 6:00 [am]{.smallcaps} to 6:00 [am]{.smallcaps} for each subsequent study day. Dosage is summarized only for days when medications were administered. Total dosing for vasoactive medications was calculated as the sum of the norepinephrine equivalent (NEE) doses for each vasoactive medication ([@R31]).

Subjects
--------

We screened all patients greater than or equal to 18 years old with hypoxemic respiratory failure daily (**Fig. [1](#F1){ref-type="fig"}**). Informed consent was obtained by qualified surrogate. Randomization blocks were stratified as either ARDS or hypoxemic respiratory failure. If patients met the criteria for ARDS (Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ ratio, chest radiograph infiltrates, absence of clinical evidence of left atrial hypertension) ([@R1]), they were stratified to the ARDS group. Otherwise patients were stratified as hypoxemic respiratory failure. Patients were randomized within 24 hours of the initiation of invasive mechanical ventilatory support.

![Consort diagram. \*Primary analysis was Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ ratio on study day 3. APRV = airway pressure release ventilation, LTV = low tidal volume, PRVC = pressure-regulated volume control, VC = volume control.](ccm-46-01943-g001){#F1}

We excluded patients with known pregnancy or a primary diagnosis of acute coronary syndrome, major cardiac dysrhythmia, severe chronic respiratory disease, or severe traumatic head injury. We also excluded patients receiving chronic mechanical ventilation, neuromuscular disease, moribund patients, or patients enrolled in another interventional trial.

Statistical Analysis
--------------------

The primary outcome was Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ at day 3. Secondary outcomes included hospital mortality, ICU and hospital length of stay (LOS), ventilator-free days (VFDs), sedation medication received, vasoactive medication received, reintubation, and barotrauma. We used the Kruskal-Wallis test for three-way comparison of the continuous outcomes and Fisher exact test for the binary outcomes. We also performed a linear regression analysis adjusted for severity of illness (using Acute Physiology and Chronic Health Evaluation II) for clinical outcomes. We compared daily administration of vasoactive medications, sedatives, benzodiazepines, opioids, atypical antipsychotics, and paralytics for each protocol. We also compared total daily dosages of continuous medications including weighted mean NEE, dexmedetomidine, and propofol. As we collected the ventilator parameters, medication information, and compliance daily for each patient, we used generalized linear mixed-effects models with the appropriate link function to estimate the mean and 95% CI for each parameter of interest. The model included a random intercept for patient, and ventilator protocol was the only fixed effect included. An *F* test for protocol effect was conducted for each model, followed by Tukey adjusted pairwise comparisons when necessary.

RESULTS
=======

Patients
--------

We enrolled a total of 52 patients in four participating ICUs with *n* equal to 17, 18, and 17 in the VC-LTV, APRV-LTV, and APRV arms, respectively (Fig. [1](#F1){ref-type="fig"}). In the mixed surgical, trauma, and medical study ICUs, the majority of patients who were screened for eligibility did not meet the inclusion criteria (Fig. [1](#F1){ref-type="fig"}). There was no difference in Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ ratio between the groups before randomization or at the time of protocol initiation (VC-LTV = 131, APRV-LTV = 98, APRV = 106; *p* = 0.78) (**Table [1](#T1){ref-type="table"}**). Baseline demographics did not differ significantly across the three arms (Table [1](#T1){ref-type="table"}).

###### 

Demographic and Baseline Information

![](ccm-46-01943-g002)

Clinical Outcomes
-----------------

In-hospital mortality for the cohort was 40% (21/52) with no significant difference among the arms (*p* = 0.20). We found no difference in day 3 Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ ratio, barotrauma, ICU LOS, hospital LOS, VFDs, or reintubation rate among the arms (**Table [2](#T2){ref-type="table"}**); this persisted after linear regression adjusted for severity of illness.

###### 

On-Study Ventilatory Parameters, Protocol Compliance, and Outcomes

![](ccm-46-01943-g003)

Ventilator Parameters
---------------------

**Figure [2](#F2){ref-type="fig"}** depicts the average daily measured V~T~ by patient for each protocol arm. Thirty-five percent of APRV and 17% of APRV-LTV patients had at least one study day with average measured release volume greater than 12 mL/kg (Fig. [2](#F2){ref-type="fig"}). Patients in the VC-LTV arm had significantly lower average daily V~T~s with less variability than those in either APRV arm (VC = 6.8 mL/kg \[6.2--7.5 mL/kg\], APRV-LTV = 8.0 mL/kg \[7.3--8.9 mL/kg\], APRV = 8.6 mL/kg \[7.8--9.6 mL/kg\]; *p* = 0.005).

![Density plot of the distribution of average daily tidal volumes by protocol. APRV = airway pressure release ventilation, LTV = low tidal volume, VC = volume control.](ccm-46-01943-g004){#F2}

We found no significant difference between P~aw~ (VC-LTV = 13.6, APRV-LTV = 15.7, APRV = 16.1; *p* = 0.15) between arms, but higher PIP in the conventional arm (VC-LTV = 23.9, APRV-LTV = 20.2, APRV = 19.5; *p* = 0.03) (Table [2](#T2){ref-type="table"}). The lowest daily MAP and highest daily CVP were also similar. Average daily compliance for each protocol was similar (*p* = 0.61) and ranged between 91% and 95% (Table [2](#T2){ref-type="table"}). Mean and [sd]{.smallcaps}s of ventilator parameters through study day 5 is presented in **Table [3](#T3){ref-type="table"}**.

###### 

Ventilator Parameters Across the Study Period
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Medication Administration
-------------------------

The proportion of patient days on which patients received vasoactive medication was 59% in the VC-LTV arm compared with 10% and 21% in the APRV arms (*p* = 0.20). We observed no significant difference in the rate of benzodiazepine receipt among the arms (VC-LTV = 9%, APRV-LTV = 8%, APRV = 18%; *p* = 0.42). Similarly, there was no statistical difference in the total dosage of dexmedetomidine (VC-LTV = 17.4 mg/kg/d, APRV-LTV = 15.4 mg/kg/d, APRV = 21.6 mg/kg/d; *p* = 0.66) or propofol medication (VC = 26.1 μg/kg/d, APRV-LTV = 26.1 μg/kg/d, APRV = 37.1 μg/kg/d; *p* = 0.17). The rate of administration of paralytics, opioids, and typical or atypical antipsychotics was also similar (Table [2](#T2){ref-type="table"}).

DISCUSSION
==========

This is the first multicenter randomized controlled trial (RCT) of an LTV ventilation APRV protocol tracking release volumes in patients with hypoxemic respiratory failure. We observed no difference in oxygenation on day 3 of mechanical ventilation between VC-LTV and APRV, although the study was underpowered. Similarly, we observed no difference in sedation requirements, VFDs, or hospital mortality among the protocols. We importantly demonstrate that in four ICUs with years of ventilator protocol experience, neither the APRV-LTV nor the standard APRV protocol was associated with adherence to a LTV (6 mL/kg) ventilation target; that both APRV protocols resulted in variable release volumes with many greater than 12 mL/kg. Despite high daily compliance, our APRV-LTV protocol was unable to achieve LTV targets. Given the evidence in support of LTV ventilation, we propose that in the absence of a protocol that demonstrates successful achievement of LTV with APRV, the use of APRV should be limited to controlled clinical trials ([@R8], [@R28]).

The mortality benefits of APRV remain unproven. APRV appears to improve oxygenation or Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ ratio in patients with hypoxemic respiratory failure ([@R5], [@R16], [@R32]--[@R42]). Although clinicians often titrate mechanical ventilation to optimize oxygenation, LTV is what confers mortality benefit, not improvement in oxygenation ([@R1]). Furthermore, clinicians titrate APRV with different application, making comparisons of published prospective studies difficult ([@R18], [@R39], [@R42]--[@R44]), and making a reproducible APRV protocol challenging. The single-center study by Zhou et al ([@R42]) favors APRV over LTV but may be contingent on the individual titration of APRV for each patient. Animal data and one observational study suggest that early application of APRV may reduce the occurrence of ARDS ([@R33], [@R39], [@R40], [@R45]--[@R48]). However, higher quality evidence indicates that LTV ventilation may be a better strategy more consistently applied for ARDS prevention ([@R7], [@R8], [@R10]--[@R12], [@R49]--[@R51]). Our study results do not suggest that APRV will improve patient comfort or reduce mortality and are supported by Lalgudi Ganesan et al ([@R52]) who found no difference in sedation and increased mortality with APRV. They suggest that a higher spontaneous-to-mandatory breath ratio observed in the APRV group could portend harm ([@R52]). Because of increased release volumes observed with APRV in our study, APRV may be inferior to VC-LTV ventilation. Although the harms of large release volumes in humans are yet unproven, animal studies demonstrate greater alveolar microstrain and decreased dynamic alveolar homogeneity with larger release volumes ([@R47], [@R53]). We assert that until implementation of APRV successfully adheres to LTV ventilation or can be tested in a reproducible manner across several centers, APRV compares unfavorably with LTV ventilation for prevention or treatment of ARDS ([@R8], [@R11], [@R52]). We express concern that although a multicenter study of APRV is justified, it may not be feasible using current protocols.

Prospective evaluations of the efficacy of APRV in patients are limited ([@R13], [@R26], [@R54], [@R55]). Our study is the second RCT comparing APRV to VC-LTV ventilation in a mixed population with acute hypoxemic respiratory failure, and the first prospective trial of an explicit APRV-LTV protocol. Maxwell et al ([@R54]) found no difference in clinical outcomes between APRV and VC-LTV in trauma patients. The single-center study by Zhou et al ([@R42]) reported an increase in VFDs and reduced sedation requirements with traditional APRV. The findings by Zhou et al ([@R42]) may be linked to key design elements as sedation and VFDs are linked; respiratory therapists manipulated APRV settings per subject and changed sedation medication to achieve spontaneous breath goals that may have introduced treatment bias ([@R42]). The individualized treatment by Zhou et al ([@R42]) of each APRV patient also raises concerns about the feasibility of reproducing the trial in other centers. Our study used explicit reproducible ventilator protocols (Supplement B, Supplemental Digital Content 2, <http://links.lww.com/CCM/E40>) that were managed by the respiratory therapists and titration of sedation was managed independent of the ventilator by the bedside nurses. Our observations do not support previously noted reduced sedation requirements with APRV ([@R25], [@R26]).

Spontaneous breathing during APRV occurs any time during the ventilator cycle and is recorded as tidal breathing. The two-way valve on the Draeger EvitaXL allows for the patient to inhale or exhale during P~low~, P~high~, or during the release phase. The majority of time during the ventilator cycle in APRV is spent at P~high~; therefore, tidal breathing occurs largely at P~high~ and generates pressures above P~high~. Many APRV protocols add tube compensation to the spontaneous efforts which enhances tidal efforts similar to pressure support. Release breaths serve to augment ventilation and are titrated ([@R28], [@R56], [@R57]). A tidal breath occurring at the end of P~high~ allows the patient to augment the release breath with exhalation of their tidal breath. Similarly, spontaneous inspiration during the ascending phase of the release breath allows the patient to inhale additional volume above that required to reach P~high~. Duration of the release breath is short, meant to prevent alveolar collapse and is determined by the time spent at P~low~ ([@R14], [@R58]). Release volume is quickly returned, is rarely tracked, yet represents the volume required to reestablish P~high~. Alveoli can collapse very quickly, and the main determinant of how much collapse occurs is the volume that leaves the lungs during P~low~. We submit that the release breath, not the spontaneous efforts in APRV, represents the volume change experienced in the alveoli. Neither Zhou et al ([@R42]) nor Maxwell et al ([@R54]) report measured release volumes. Our findings highlight the variability in measured release and spontaneous breaths during APRV ventilation (Fig. [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

Inconsistent V~T~s with corresponding increases in transalveolar pressure may confer risk of VILI during spontaneous efforts in mechanically ventilated patients and such variability is common in APRV ([@R38], [@R52], [@R57], [@R59]--[@R62]). Increased driving pressure and transalveolar pressures may be more directly related to VILI ([@R60], [@R61]). In our findings, 35% of APRV and 17% of APRV-LTV patients had at least one study day where the average measured release volume was greater than 12 mL/kg (Fig. [2](#F2){ref-type="fig"}) which supports concerns about potential harms ([@R28], [@R61], [@R63]). The P~aw~ in APRV is often considered to be similar to the intrinsic PEEP required by the patient to achieve the critical opening pressure on the hysteresis curve but often it approaches P~high~ ([@R28], [@R64], [@R65]). In our study, both APRV protocols demonstrated numerically higher P~aw~ compared with VC-LTV. Spontaneous breaths at higher P~aw~ may result in even higher transalveolar pressures with unknown risks ([@R28], [@R37], [@R61], [@R63], [@R64]). Additional clinical studies measuring transalveolar pressure during release breaths and spontaneous efforts on APRV are warranted.

This study has several limitations. Clinicians were not blinded to the treatment arm. Although our study is comparable in size to other APRV trials ([@R52], [@R54]), we did not reach our target enrollment. Our study is thus underpowered, and negative findings of this trial may represent type 2 statistical error. The study was originally designed to evaluate oxygenation but was stopped prematurely due to inability to achieve LTV in APRV. Our patient enrollment was also smaller than enrollment in the trial by Zhou et al ([@R42]). However, our study cohort and mortality rate (consistent with severe to moderate ARDS) are representative of the population that currently triggers the clinical use of APRV ([@R66]). Our study protocol did not include an explicit sedation, pain management, or vasoactive medication protocol. Titration of sedation and pain control were performed by bedside clinicians using standard goal-directed delirium (Confusion Assessment Method for the ICU) and sedations assessments (Richmond Agitation-Sedation Scale). Similarly, vasoactive medications were titrated to goal MAP determined by the clinical team. It is possible that patients in the APRV arms were inappropriately perceived as more agitated or uncomfortable. Our data, however, are likely to mimic clinical application of sedation management with score-targeted sedation guidelines. Our findings may be specific to our protocol. It is unclear why titration of P~low~ and P~high~ did not result in targeted release breath values or if a different APRV-LTV protocol can achieve an average V~T~ less than 6.5 mL/kg. Although daily compliance was high, we used a paper protocol without assessment of compliance to each individual instruction. It is possible that an electronic APRV protocol would have tracked compliance more accurately and identified areas where the APRV-LTV protocol could have been changed to better achieve LTV targets.

CONCLUSIONS
===========

An APRV-LTV protocol was implemented with adequate protocol compliance and resulted in highly variable release volumes that do not consistently achieve an LTV target (\< 6.5 mL/kg). Average daily release volumes often exceeded 12 mL/kg. Our APRV-LTV protocol designed to limit release volumes was not feasible. Current APRV protocols are unable to achieve consistent and reproducible delivery of LTV ventilation goals. A large- scale efficacy trial of APRV-LTV is not feasible in the absence of a reproducible and easily generalizable APRV-LTV protocol.
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